EP2703815A1 - Verfahren zur bestimmung der prognose von niereninsuffizienz - Google Patents

Verfahren zur bestimmung der prognose von niereninsuffizienz Download PDF

Info

Publication number
EP2703815A1
EP2703815A1 EP12777358.8A EP12777358A EP2703815A1 EP 2703815 A1 EP2703815 A1 EP 2703815A1 EP 12777358 A EP12777358 A EP 12777358A EP 2703815 A1 EP2703815 A1 EP 2703815A1
Authority
EP
European Patent Office
Prior art keywords
fgf
antibody
measuring
reagent
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12777358.8A
Other languages
English (en)
French (fr)
Other versions
EP2703815A4 (de
Inventor
Takayuki HAMANO
Yoshitaka Isaka
Isao Matsui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hitachi Chemical Diagnostics Systems Co Ltd
Original Assignee
Kyowa Medex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Medex Co Ltd filed Critical Kyowa Medex Co Ltd
Publication of EP2703815A1 publication Critical patent/EP2703815A1/de
Publication of EP2703815A4 publication Critical patent/EP2703815A4/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to methods for determining the prognosis of renal failure and kits for determining the prognosis of renal failure.
  • Fibroblast growth factor-23 (hereinafter, referred to as FGF-23) is a member of the fibroblast growth factor (FGF) family and a polypeptide consisting of 251 amino acids, which is produced mainly in bone tissues and acts on the kidney to inhibit reabsorption of phosphorus in the renal tubules.
  • FGF-23 fibroblast growth factor
  • FGF-23 fibroblast growth factor
  • Measuring FGF-23 in the blood is recognized as being useful for monitoring the pathological conditions of these diseases, and thus, FGF-23 is drawing attention as a marker in recent years (Patent Document 1).
  • 25-Hydroxyvitamin D (hereinafter, referred to as 25(OH)D) is a substance produced by hydroxylation in the liver of position 25 in the side chain of vitamin D which was absorbed into the body. In the body, this is further metabolized to 1 ⁇ ,25-dihydroxyvitamin D [1 ⁇ ,25(OH) 2 D] or 24,25-dihydroxyvitamin D [24,25(OH) 2 D] in the kidney by hydroxylation at position 1 or 24.
  • Vitamin D itself has little physiological activity, and is generally seldom measured since its blood concentration varies greatly due to metabolism, transfer to fat tissues, and such. In the body, vitamin D is quickly metabolized by 25-hydroxylase in the liver and is converted to 25(OH)D, which is then further metabolized in the kidney to the active-form 1 ⁇ ,25-dihydroxyvitamin D by hydroxylation at position1 ⁇ by 1 ⁇ -hydroxylase.
  • Active-form 1 ⁇ ,25-dihydroxyvitamin D promotes absorption of calcium and phosphorus from the small intestine, and promotes elution of bone minerals from the bones. Furthermore, it promotes resorption of calcium and phosphorus in the kidney and contributes to maintenance of homeostasis of calcium and phosphorus in a living body.
  • Vitamin D deficiency causes rickets in children and osteomalacia and osteoporosis in adults. Measurement of 25(OH)D is recognized as being useful for monitoring the pathological conditions of vitamin D deficiency and insufficiency (Non-Patent Document 2).
  • Patent Document 1 WO 2003/057733
  • An objective of the present invention is to provide methods and kits for determining the prognosis of renal failure, which are effective for deciding on a therapeutic strategy for patients with renal failure.
  • the present inventors carried out dedicated studies to solve the above-described problems and found that the prognosis of renal failure can be determined by measuring FGF-23 and 25(OH)D in a sample and making an evaluation by combining those measured values, and completed the present invention. More specifically, the present invention relates to [1] to [6] below:
  • the present invention enables selection of a group of renal failure patients with poor prognosis, and provides a method and a kit for determining the prognosis of renal failure, which are useful for deciding on a therapeutic strategy such as selection of medication, introduction of a stricter diet therapy and early introduction of dialysis treatment.
  • the method of the present invention for determining the prognosis of renal failure comprises measuring FGF-23 and 25(OH)D in a biological sample.
  • the method of the present invention for determining the prognosis of renal failure includes, for example, the following steps:
  • step [5] when the median value of the FGF-23 concentrations and the median value of the 25(OH)D concentrations that were determined based on the FGF-23 concentrations and 25(OH)D concentrations of all of the biological samples subjected to measurement are, for example, 49.4 pg/mL and 23.0 ng/mL, respectively, the prognosis of renal failure of a subject whose FGF-23 concentration is 49.4 pg/mL or more and the 25(OH)D concentration is less than 23.0 ng/mL can be determined as being poor, and the prognosis of renal failure of a subject whose FGF-23 concentration is less than 49.4 pg/mL and the 25(OH)D concentration is 23.0 ng/mL or more can be determined as being good.
  • the median value of the FGF-23 concentrations means the concentration of FGF-23 positioned exactly in the middle when FGF-23 concentrations determined for all the biological samples are arranged in order from the lowest value.
  • the median value of the 25(OH)D concentrations means the concentration of 25(OH)D positioned exactly in the middle when 25(OH)D concentrations determined for all the biological samples are arranged in order from the lowest value.
  • the biological sample of the present invention is not particularly limited as long as it is a sample that enables the measurement of FGF-23 and 25(OH)D, and examples include whole blood, serum, and plasma; and serum and plasma are preferred.
  • the method for measuring FGF-23 is not particularly limited as long as it is a method that enables a measurement of FGF-23, and examples include an immunological measurement method in which a measurement is carried out using FGF-23-binding antibodies.
  • an immunological measurement method include any method that utilizes an antigen-antibody reaction, such as an immunoassay, an immunoblotting, an agglutination reaction, a complement fixation reaction, a hemolytic reaction, a precipitation reaction, a gold colloid method, a chromatography, and an immunostaining; and an immunoassay is preferred.
  • An immunoassay is a method of detecting or quantifying an antibody or an antigen using an antigen or an antibody labeled with various types of label, and depending on the method of labeling the antigen or antibody, examples include a radioimmunoassay (RIA), an enzyme immunoassay (EIA or ELISA), a chemiluminescent enzyme immunoassay (CLEIA or CLIA), a fluorescent immunoassay (FIA), a luminescent immunoassay, a physicochemical measurement method (TIA, LAPIA, and PCIA), and a flow cytometry; and a chemiluminescent enzyme immunoassay and such is preferred.
  • an immunoassay may be a sandwich method or a competition method.
  • Measurement of FGF-23 in a biological sample using immunoassay can be carried out, for example, by the following method:
  • a washing step may be inserted between step [1] and step [2] mentioned above.
  • the label is not particularly limited as long as it binds to the anti-FGF-23 antibody and enables measurement of FGF-23, and examples include peroxidase, alkaline phosphatase, ⁇ -galactosidase, a fluorescent substance, and a luminescent substance.
  • the fluorescent substance include FITC (fluorescein isothiocyanate), RITC (rhodamine B-isothiocyanate), quantum dot ( Science, 281, 2016-2018, 1998 ), phycobiliproteins such as phycoerythrin, GFP (Green fluorescent Protein), RFP (Red fluorescent Protein), YFP (Yellow fluorescent Protein), and BFP (Blue fluorescent Protein).
  • the luminescent substance include acridinium and derivatives thereof, a ruthenium complex compound, and lophine.
  • FGF-23 can be measured using a commercially available FGF-23-measuring kit.
  • the commercially available FGF-23-measuring kit include the "FGF-23 assay reagent" (manufactured by KAINOS Laboratories, Inc.).
  • the method for measuring 25(OH)D is not particularly limited as long as it is a method that enables a measurement of 25(OH)D, and examples include an immunological measurement method in which a measurement is carried out using antibodies against 25(OH)D.
  • the immunological measurement method include any method that utilizes an antigen-antibody reactions, such as an immunoassay, an immunoblotting, an agglutination reaction, a complement fixation reaction, a hemolytic reaction, a precipitation reaction, a gold colloid method, a chromatography, and an immunostaining.
  • the method for measuring 25(OH)D is preferably, for example, an immunoassay method.
  • immunoassay examples include the aforementioned measurement methods.
  • Measurement of 25(OH)D in a biological sample using an immunoassay can be carried out, for example, by the following method:
  • a washing step may be inserted between step [1] and step [2] mentioned above.
  • the label is not particularly limited as long as it binds to the anti-25(OH)D antibody and enables measurement of 25(OH)D, and examples include the aforementioned labels.
  • 25(OH)D can be measured using a commercially available 25(OH)D-measuring kit.
  • the commercially available 25(OH)D-measuring kit include "LIAISON 25 OH Vitamin D TOTAL Assay” (manufactured by DiaSorin S.p.A.), and "25-OH Vitamin D, Direct ELISA Kit” (manufactured by Immundiagnostik AG).
  • the kit for determining the prognosis of renal failure of the present invention is a kit used for the method for determining the prognosis of renal failure of the present invention, and comprises a reagent for measuring FGF-23 and a reagent for measuring 25(OH)D.
  • the kit of the present invention may also comprise a diluent for a biological sample, a reaction buffer, a washing solution, a reagent for detecting the label, and such.
  • a device suitable for a measurement may be combined to produce the kit of the present invention.
  • the reagent for measuring FGF-23 is not particularly limited as long as it is a reagent that enables a measurement of FGF-23 in a biological sample, and examples include: (1) a reagent comprising a first antibody that binds to FGF-23 and that is immobilized onto a carrier and a labeled second antibody in which a label is bound to a second antibody that binds to FGF-23; (2) a reagent comprising an antibody that binds to FGF-23 and that is immobilized onto a carrier and a labeled competitive substance in which a label is bound to a competitive substance that competes with FGF-23; and (3) a reagent comprising a competitive substance that competes with FGF-23 and that is immobilized onto a carrier and a labeled antibody in which a label is bound to an FGF-23-binding antibody.
  • a diluent for a biological sample, a reaction buffer, a washing solution, a reagent for detecting the label, a standard material for FGF-23, and such may also be comprised in a reagent for measuring FGF-23.
  • the antibody that binds to FGF-23 is not particularly limited as long as it is an antibody that binds to FGF-23, and examples include an anti-FGF-23 antibody from a goat, a rabbit, a rat, a mouse and such.
  • the anti-FGF-23 antibody may be a polyclonal antibody or a monoclonal antibody.
  • a fragment of anti-FGF-23 antibody may also be used.
  • the antibody fragment include an antibody fragment with the Fc portions removed, such as Fab obtained by papain treatment of an antibody, F(ab') 2 obtained by pepsin treatment of an antibody, and Fab' obtained by pepsin treatment and reduction treatment of an antibody.
  • the antigen-recognition site of the first antibody and the antigen-recognition site of the second antibody may be the same or different, and they are preferably different.
  • the competitive substance that competes with FGF-23 is not particularly limited as long as it is a substance that can compete with FGF-23, and examples include FGF-23 itself and a substance comprising a peptide corresponding to an antigen-recognition site of an anti-FGF-23 antibody.
  • the carrier is not particularly limited as long as it is a carrier that enables measurement of FGF-23, and examples include a plate, a latex, and magnetic particles.
  • Examples of an immobilization of the anti-FGF-23 antibody and the competitive substance to the carrier include a physical method and a chemical method.
  • Examples of a physical method include a method using a physical adsorption.
  • Examples of a chemical method include a method using an avidin-biotin interaction and a method using a linker.
  • the diluent for a biological sample is not particularly limited as long as it is a diluent that enables measurement of FGF-23, and examples include an aqueous solution in which a surfactant, a protein, and such are contained in an aqueous medium.
  • examples of the aqueous medium include a deionized water, a distilled water, and a buffer.
  • the buffer include a phosphate buffer and a Good's buffer.
  • Examples of the Good's buffer include 2-morpholinoethanesulfonic acid (MES) buffer, bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris) buffer, tris(hydroxymethyl)aminomethane (Tris) buffer, N -(2-acetoamido)imino diacetic acid (ADA) buffer, piperazine- N,N '-bis(2-ethanesulfonic acid) (PIPES) buffer, 2-[ N -(2-acetamido)amino]ethanesulfonic acid (ACES) buffer, 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO) buffer, 2-[ N,N -bis(2-hydroxyethyl)amino]ethanesulfonic acid (BES) buffer, 3-morpholinopropanesulfonic acid (MOPS) buffer, 2- ⁇ N -[tris(hydroxymethyl)methyl]amino ⁇ ethanesulfonic acid (
  • the surfactant is not particularly limited as long as it is a surfactant that enables measurement of FGF-23, and examples include a nonionic surfactant, a cationic surfactant, an anionic surfactant, and an amphoteric surfactant.
  • examples of the proteins include bovine serum albumin (BSA), fetal bovine serum (FBS), casein, and BlockAce (manufactured by Dainippon Pharmaceutical Co., Ltd.).
  • the reaction buffer is not particularly limited as long as it is a buffer that enables measurement of FGF-23, and examples include the aforementioned buffer.
  • a surfactant, a protein, a metal ion, a sugar, an antiseptic, and such may be included in the reaction buffer as necessary.
  • the surfactant include the aforementioned surfactant.
  • the protein include the aforementioned protein.
  • the metal ion include magnesium ion, manganese ion, and zinc ion.
  • Examples of the sugar include mannitol and sorbitol.
  • the antiseptic include sodium azide, an antibiotic (streptomycin, penicillin, gentamicin, etc.), and BioAce.
  • the washing solution is not particularly limited as long as it is a washing solution that enables measurement of FGF-23, and examples include a phosphate buffered saline (10 mmol/L phosphate buffer containing 0.15 mol/L sodium chloride, pH7,2) (PBS). As necessary, the aforementioned surfactant, protein, antiseptic, and such may be included in the washing solution.
  • the reagent for measuring the label is a reagent for measuring the label in the immunocomplex produced by antigen-antibody reaction, and it is not particularly limited as long as it is a reagent for measuring the label that enables measurement of FGF-23.
  • the label is not particularly limited as long as it is a label that binds to an anti-FGF-23 antibody and enables measurement of FGF-23, and examples include peroxidase, alkaline phosphatase, and ⁇ -galactosidase.
  • the aforementioned surfactant, protein, metal ion, sugar, antiseptic, and such may be included in the reagent for measuring the label.
  • examples of the reagent for measuring the label include a reagent comprising hydrogen peroxide and a fluorescent substrate, and a reagent comprising hydrogen peroxide and a luminescent substrate.
  • the fluorescent substrate include 4-hydroxyphenyl acetic acid, 3-(4-hydroxyphenyl)propionic acid, and coumarin.
  • Examples of the luminescent substrate include the luminol compound and the lucigenin compound.
  • examples of the reagent for measuring the label include a reagent comprising a substrate of alkaline phosphatase.
  • Examples of the substrate of alkaline phosphatase include 3-(2'-spiroadamantane)-4-methoxy-4-(3'-phosphoryloxy)phenyl-1,2-dioxetane disodium salt (AMPPD), 2-chloro-5- ⁇ 4-methoxyspiro[1,2-dioxetane-3,2'-(5'-chloro)tricyclo[3.3.1.13,7]cane]-4-yl ⁇ phenyl phosphate disodium salt (CDP-StarTM), 3- ⁇ 4-methoxyspiro[1,2-dioxetane-3,2'-(5'-chloro)tricyclo[3.3.1.13,7]decane]-4-yl ⁇ phenylphosph ate disodium salt (CSPDTM), [10-methyl-9(10H)-acridinylidene]phenoxymethylphosphate disodium salt (LumigenTM APS-5), and 9-(4-chlorophen
  • examples of the reagent for measuring the label include a reagent comprising a substrate of ⁇ -galactosidase.
  • examples of the substrate of ⁇ -galactosidase include 4-methylumbelliferyl- ⁇ -D-galactopyranoside, Galacton-Plus (manufactured by Applied Biosystems Inc.), and other similar compounds.
  • Examples of a standard material include FGF-23 obtained by a genetic engineering technique or obtained from a biological sample, and cells expressing FGF-23.
  • the reagent for measuring 25(OH)D is not particularly limited as long as it is a reagent that enables a measurement of 25(OH)D in a biological sample, and examples include: (1) a reagent comprising a first antibody that binds to 25(OH)D and that is immobilized onto a carrier and a labeled second antibody in which a label is bound to a second antibody that binds to 25(OH)D; (2) a reagent comprising an antibody that binds to 25(OH)D and that is immobilized onto a carrier and a labeled competitive substance in which a label is bound to a competitive substance that competes with 25(OH)D; and (3) a reagent comprising a competitive substance that competes with 25(OH)D and that is immobilized onto a carrier and a labeled antibody in which a label is bound to an antibody that binds to 25(OH)D.
  • a diluent for a biological sample, a reaction buffer, a washing solution, a reagent for detecting the label, a standard material for 25(OH)D, and such may also be comprised in the reagent for measuring 25(OH)D.
  • the antibody that binds to 25(OH)D is not particularly limited as long as it is an antibody that binds to 25(OH)D, and examples include anti-25(OH)D antibody from a goat, a rabbit, a rat, a mouse, and such.
  • the anti-25(OH)D antibody may be a polyclonal antibody or a monoclonal antibody. Fragment of anti-25(OH)D antibody may also be used. Examples of the antibody fragment include the aforementioned fragment.
  • the antigen-recognition site of the first antibody and the antigen-recognition site of the second antibody may be the same or different, and they are preferably different.
  • the competitive substance that competes with 25(OH)D is not particularly limited as long as it is a substance that can compete with 25(OH)D, and examples include 25(OH)D itself and a substance having a partial structure of the 25(OH)D molecule that corresponds to the antigen-recognition site of an anti-25(OH)D antibody.
  • the carrier is not particularly limited as long as it is a carrier that enables measurement of 25(OH)D, and examples include the aforementioned carrier.
  • Examples of immobilization of the anti-25(OH)D antibody and the competitive substance to the carrier include the aforementioned immobilization method.
  • the diluent for a biological sample is not particularly limited as long as it is a diluent that enables measurement of 25(OH)D, and examples include the aforementioned diluent.
  • the reaction buffer is not particularly limited as long as it is a buffer that enables measurement of 25(OH)D, and examples include the aforementioned buffer.
  • the aforementioned surfactant, protein, metal ion, sugar, antiseptic, and such may be included in the reaction buffer.
  • the washing solution is not particularly limited as long as it is a washing solution that enables measurement of 25(OH)D, and examples include the aforementioned washing solution.
  • the reagent for measuring the label is not particularly limited as long as it is a reagent for measuring the label that enables measurement of 25(OH)D.
  • the label is not particularly limited as long as it is a label that binds to an anti-25(OH)D antibody and enables measurement of 25(OH)D, and examples include the aforementioned label.
  • Examples of the reagent for measuring the label include the aforementioned reagent for measuring the label.
  • the aforementioned surfactant, protein, metal ion, sugar, antiseptic, and such may be included in the reagent for measuring the label.
  • Examples of the standard material include 25(OH)D prepared from a biological sample or chemically synthesized 25(OH)D. Commercially available 25(OH)D may also be used as the standard material.
  • Blood samples consisting of whole blood, serum, and plasma, as well as urine samples were collected at the time of patient registration. The blood samples were centrifuged within 30 minutes and the obtained serum were stored by freezing at -80°C until measurement. Creatinine, albumin, calcium, and inorganic phosphorus were measured and eGFR was calculated for each type of sample. eGFR was calculated according to the Japanese standard method based on inulin clearance.
  • Fig. 1 shows the relationship between the various risk factors and the hazard ratios, and the three numerical values of the various risk factors refer to, from the left, the hazard ratio, the lower limit of the 95% confidence interval, and the upper limit of the 95% confidence interval.
  • the hazard ratio is a value that indicates how many times the occurrence of a renal event is increased in the group with the specific risk factor when the group negative for urinary protein [Proteinuria (-)] is used as the control group.
  • the 95% confidence interval is the range in which the population mean is included at a probability of 95%.
  • the hazard ratio for renal events showed a tendency to increase as the concentration shifted from high to low concentration, and the hazard ratio was highest (HR, 11.5) in the group with the lowest concentration (less than 10 ng/mL).
  • the hazard ratio for renal events showed a tendency to increase in the high-concentration groups, and the hazard ratios were shown to increase as the FGF-23 concentration increased, in the order of: group Q2, group Q3, group Q4, and group Q5.
  • the median value of the 25(OH)D concentrations of all the subjects was 23.0 ng/mL, and the median value of the FGF-23 concentrations of all the subjects was 49.4 pg/mL. Therefore, 25(OH)D concentration of less than 23.0 ng/mL was defined as the low level group and 25(OH)D concentration of 23.0 ng/mL or more was defined as the high level group; and FGF-23 concentration of less than 49.4 pg/mL was defined as the low level group and FGF-23 concentration of 49.4 pg/mL or more was defined as the high level group.
  • subjects were categorized into four groups: the low 25(OH)D concentration level and low FGF-23 concentration level group (df group); the high 25(OH)D concentration level and low FGF-23 concentration level group (Df group); the low 25(OH)D concentration level and high FGF-23 concentration level group (dF group); and the high 25(OH)D concentration level and high FGF-23 concentration level group (DF group).
  • Their Kaplan-Meier survival curves for renal events (doubling of serum creatinine or introduction of dialysis treatment) for approximately five years were prepared.
  • a Kaplan-Meier survival curve shows, for each of the four groups, the probability of survival without development of renal events in relation to the number of days.
  • Fig. 3 shows the Kaplan-Meier survival curves prepared based on data before correction for age, gender, diabetes, cardiovascular disease history, hypertension, hemoglobin, serum albumin, urinary protein, eGFR, serum calcium, serum phosphorus, calcitriol, whole PTH, season of blood collection, administration of ACE inhibitor/ARB, administration of active-form vitamin D, and administration of calcium
  • Fig. 4 shows the Kaplan-Meier survival curves prepared based on corrected data.
  • the high 25(OH)D concentration level and low FGF-23 concentration level group (Df group) was used as the standard, and the hazard ratio (HR) and 95% confidence interval (95% C.I.) were 1.47 and 0.63-3.43, respectively, for the low 25(OH)D concentration level and low FGF-23 concentration level group (df group); the hazard ratio (HR) and 95% confidence interval (95% C.I.) were 1.96 and 0.88-4.36, respectively, for the high 25(OH)D concentration level and high FGF-23 concentration level group (DF group); and the hazard ratio (HR) and 95% confidence interval (95% C.I.) were 2.53 and 1.14-5.64, respectively, for the low 25(OH)D concentration level and high FGF-23 concentration level group (dF group). Therefore, the low 25(OH)D concentration level and high FGF-23 concentration level group (dF group) was confirmed to show the highest risk for renal events.
  • the present invention provides a method and a kit for determining the prognosis of renal failure, which are useful for deciding on a therapeutic strategy for patients with renal failure.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP12777358.8A 2011-04-25 2012-04-23 Verfahren zur bestimmung der prognose von niereninsuffizienz Withdrawn EP2703815A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011096718 2011-04-25
PCT/JP2012/060818 WO2012147670A1 (ja) 2011-04-25 2012-04-23 腎不全の予後判定方法

Publications (2)

Publication Number Publication Date
EP2703815A1 true EP2703815A1 (de) 2014-03-05
EP2703815A4 EP2703815A4 (de) 2015-03-04

Family

ID=47072190

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12777358.8A Withdrawn EP2703815A4 (de) 2011-04-25 2012-04-23 Verfahren zur bestimmung der prognose von niereninsuffizienz

Country Status (8)

Country Link
US (1) US20140147936A1 (de)
EP (1) EP2703815A4 (de)
JP (1) JP6012108B2 (de)
KR (1) KR20140037094A (de)
CN (1) CN103608676A (de)
CA (1) CA2833118A1 (de)
TW (1) TW201250248A (de)
WO (1) WO2012147670A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104502596A (zh) * 2014-12-23 2015-04-08 温州医科大学 一种慢性肾病诊断试剂盒
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
US11099191B2 (en) * 2016-05-17 2021-08-24 Osaka University Kidney disease prognosis prediction method and system
WO2018221544A1 (ja) * 2017-05-31 2018-12-06 協和メデックス株式会社 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット
CN109100512A (zh) * 2018-08-02 2018-12-28 宁波奥丞生物科技有限公司 一种检测egfr的化学发光试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048058A1 (en) * 2001-12-28 2005-03-03 Yuji Yamazaki Antibody against fibroblast growth factor-23
WO2007039194A1 (en) * 2005-09-29 2007-04-12 Roche Diagnostics Gmbh Release reagent for vitamin d compounds
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
WO2010091236A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198959A1 (en) * 2002-03-28 2003-10-23 Kurnit David M. Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases
PL1831699T3 (pl) * 2004-12-20 2010-04-30 Antibodyshop As Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
EP1977250A1 (de) * 2006-01-20 2008-10-08 mosaiques diagnostics and therapeutics AG Verfahren und marker für die diagnose von nierenkrankheiten
AU2010210537B2 (en) * 2009-02-06 2015-06-18 Astute Medical, Inc. Diagnosis and prognosis of renal injury and renal failure
JP5775874B2 (ja) * 2009-08-28 2015-09-09 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048058A1 (en) * 2001-12-28 2005-03-03 Yuji Yamazaki Antibody against fibroblast growth factor-23
WO2007039194A1 (en) * 2005-09-29 2007-04-12 Roche Diagnostics Gmbh Release reagent for vitamin d compounds
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
WO2010091236A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. ROJAS-RIVERA ET AL: "The expanding spectrum of biological actions of vitamin D", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 25, no. 9, 3 June 2010 (2010-06-03), pages 2850-2865, XP055162640, ISSN: 0931-0509, DOI: 10.1093/ndt/gfq313 *
P.-A. WESTERBERG ET AL: "Regulation of fibroblast growth factor-23 in chronic kidney disease", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 22, no. 11, 5 June 2007 (2007-06-05), pages 3202-3207, XP055162654, ISSN: 0931-0509, DOI: 10.1093/ndt/gfm347 *
See also references of WO2012147670A1 *

Also Published As

Publication number Publication date
EP2703815A4 (de) 2015-03-04
CA2833118A1 (en) 2012-11-01
CN103608676A (zh) 2014-02-26
TW201250248A (en) 2012-12-16
US20140147936A1 (en) 2014-05-29
KR20140037094A (ko) 2014-03-26
JP6012108B2 (ja) 2016-10-25
JPWO2012147670A1 (ja) 2014-07-28
WO2012147670A1 (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
US8969018B2 (en) Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8524462B2 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
US20190376961A1 (en) Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor
JP5032372B2 (ja) 透析の必要性を予測するためのｂｎｐ型ペプチド類の使用
EP2583104B1 (de) Vorhersage und Erkennung einer akuten Nierenverletzung nach der Operation
EP2281203A1 (de) Marker für implantatfehler und mortalität
US11435367B2 (en) Methods and kits for assaying a vitamin D moiety
EP2703815A1 (de) Verfahren zur bestimmung der prognose von niereninsuffizienz
JP2014526676A (ja) Ｌ−ｆａｂｐに基づく、急性事象後または外科的介入後の腎障害の診断

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131017

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192012

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20150202

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/82 20060101ALI20150127BHEP

Ipc: G01N 33/74 20060101AFI20150127BHEP

Ipc: G01N 33/68 20060101ALI20150127BHEP

17Q First examination report despatched

Effective date: 20151120

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170306

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170718

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192012

Country of ref document: HK